Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference  held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is “Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)”. This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional … Continue reading Biotech Active Runners: Hemispherx BioPharma (NYSEMKT:HEB), Rexahn Pharmaceuticals (NYSEMKT:RNN), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Small Cap Active Stocks: FuelCell Energy (NASDAQ:FCEL), Ariad Pharmaceuticals (NASDAQ:ARIA), KB Home (NYSE:KBH), Endocyte (NASDAQ:ECYT)

Shares of Plug Power Inc. (NASDAQ:FCEL) fell 9% on Friday, and the stock was moving toward ending the week down nearly 20% as investors’ enthusiasm for it seemed to have dried up — at least for now. FuelCell Energy Inc (NASDAQ:FCEL) stock performance was 6.64% in last session and finished the day at $2.57. Traded volume was 29.87million shares in the last session and the … Continue reading Small Cap Active Stocks: FuelCell Energy (NASDAQ:FCEL), Ariad Pharmaceuticals (NASDAQ:ARIA), KB Home (NYSE:KBH), Endocyte (NASDAQ:ECYT)

NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock … Continue reading NASDAQ Gainers: Ariad Pharmaceuticals (NASDAQ:ARIA), Yandex NV (NASDAQ:YNDX), GT Advanced Technologies (NASDAQ:GTAT), Oculus Innovative Sciences (NASDAQ:OCLS)